691856-86-7

Basic information

• Product Name: 2-(4-FLUORO-PHENYL)-5-HYDROXY-BENZOFURAN-3-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 2-(4-fluorophenyl)-5-hydroxy-3-BenzofuranCarbocylic acid ethyl ester;2-(4-FLUORO-PHENYL)-5-HYDROXY-BENZOFURAN-3-CARBOXYLIC ACID ETHYL ESTER;3-Benzofurancarboxylic acid, 2-(4-fluorophenyl)-5-hydroxy-, ethyl ester;ethyl 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate
• CAS NO: 691856-86-7
• Molecular Formula: C₁₇H₁₃FO₄
• Molecular Weight: 300.2811232
• Mol File: 691856-86-7.mol

Chemical Properties

• Boiling Point: 468.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.313±0.06 g/cm3(Predicted)
• PKA: 8.28±0.40(Predicted)
• CAS DataBase Reference: 2-(4-FLUORO-PHENYL)-5-HYDROXY-BENZOFURAN-3-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-FLUORO-PHENYL)-5-HYDROXY-BENZOFURAN-3-CARBOXYLIC ACID ETHYL ESTER(691856-86-7)
• EPA Substance Registry System: 2-(4-FLUORO-PHENYL)-5-HYDROXY-BENZOFURAN-3-CARBOXYLIC ACID ETHYL ESTER(691856-86-7)

Safety Data

• Hazardous Substances Data: 691856-86-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
2-(4-FLUORO-PHENYL)-5-HYDROXY-BENZOFURAN-3-CARBOXYLIC ACID ETHYL ESTER is used as a building block for the synthesis of pharmaceuticals and other biologically active compounds, due to its unique structural features and potential biological activities.
Used in Drug Development:
In the pharmaceutical industry, 2-(4-FLUORO-PHENYL)-5-HYDROXY-BENZOFURAN-3-CARBOXYLIC ACID ETHYL ESTER is used as a precursor in the development of new drugs, leveraging its potential therapeutic properties and pharmacological effects for various medical applications.
Used in Research and Development:
2-(4-FLUORO-PHENYL)-5-HYDROXY-BENZOFURAN-3-CARBOXYLIC ACID ETHYL ESTER is utilized in research and development settings to study its pharmacological effects and explore its potential as a therapeutic agent for various diseases and conditions.

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 1999-00-4 ethyl 3-(4'-fluorophenyl)-3-oxopropionate 
• 106-51-4 p-benzoquinone 
• 403-42-9 1-(4-fluorophenyl)ethanone 

Downstream Products

• 1374235-00-3 C₁₉H₁₄FNO₅ 
• 1374235-01-4 C₁₉H₁₆FNO₃ 
• 1374235-02-5 C₂₀H₁₈FNO₅S 

Relevant articles and documents

Design, synthesis and in vitro anti-bacterial activities of benzofuran-isatin hybrids

A series of novel benzofuran-isatin hybrids 6a-x tethered through propylene, butylene, pentylene and hexylene were designed, synthesized and evaluated for their in vitro antibacterial activities against a panel of clinically important Gram-positive and Gr

Benzofuran-isatin conjugates as potent VEGFR-2 and cancer cell growth inhibitors

A series of benzofuran-isatin conjugates 6a-l and 7a,b tethered by various alkyl linkers were synthesized and evaluated for their VEGFR-2 inhibitory activity and in vitro activity against a panel of cancer cell lines. Seven of them were comparable with or

Benzofuran-isatin-hydroxylimine/thiosemicarbazide hybrids: Design, synthesis and in vitro anti-mycobacterial activity evaluation

A series of novel benzofuran-isatin-hydroxylimine/thiosemicarbazide hybrids were designed, synthesized and evaluated for their in vitro anti-TB activities against drug-sensitive MTB H37Rv and MDR-TB isolates as well as cytotoxicity. All benzofu

Benzofuran–isatin Hybrids: Design, Synthesis, and In Vitro Anti-cancer Activities

A series of novel benzofuran–isatin hybrids 6a–s tethered through propylene and butylene were designed, synthesized, and evaluated for their in vitro anti-cancer activities against HepG2 (liver carcinoma), Hela (cervical cancer), A549 (lung adenocarcinoma

Design, synthesis and in vitro anti-bacterial activities of benzofuran-isatin hybrids

A series of novel benzofuran-isatin hybrids 6a-x tethered through propylene, butylene, pentylene and hexylene were designed, synthesized and evaluated for their in vitro antibacterial activities against a panel of clinically important Gram-positive and Gr

Benzofuran-isatin-imine hybrids tethered via different length alkyl linkers: Design, synthesis and in vitro evaluation of anti-tubercular and anti-bacterial activities as well as cytotoxicity

Herein we report the design and synthesis of twenty-two novel benzofuran-isatin-imine hybrids 7a-v tethered through propylene, butylene, pentylene and hexylene, and for the evaluation of their in vitro anti-tubercular and anti-bacterial activities as well

Benzofuran-isatin hybrids tethered via different length alkyl linkers and their in vitro anti-mycobacterial activities

A series of novel benzofuran-isatin hybrids 6a–m tethered through different length alkyl linkers propylene, butylene, pentylene and hexylene were designed, synthesized and evaluated for their in vitro anti-mycobacterial activities against both drug-suscep

A kind of benzofuran and benzofuran coumarin derivative and its preparation method and application (by machine translation)

The invention discloses a formula (I), (II), (III), (IV) shown benzofurans and Coumestans derivative and its preparation method, and said styrene and furan and Coumestans derivative compound in the treatment of multi-drug resistant tuberculosis disease in the application. The invention surfactant and furan and Coumestans derivatives are a class of novel structure, the bacteriostatic effect is prominent anti-Mycobacterium tuberculosis compound, it is to Mycobacterium tuberculosis pks13 gene fragment encoding polyketide synthase as the acting target, inhibit the growth and reproduction of microorganisms, in particular inhibiting Mycobacterium tuberculosis in bacterial cell wall synthesis of branch, in the medical field has potential application prospect. (by machine translation)

Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold

This letter describes the discovery of a fused benzofuran scaffold viable for preparing a series of novel potent HCV NS5B polymerase non-nucleoside inhibitors. Designed on the basis of the functionalized benzofuran derivative nesbuvir (HCV-796), these com

Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis

Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery. The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids. Small molecules targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compound whose X-ray cocrystal structure has been very recently solved. Its initial inactivity in a serum inhibition titration (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability. Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT. Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.